Korro Bio (KRRO) Projected to Announce Quarterly Earnings on Wednesday

Korro Bio (NASDAQ:KRRO) is anticipated to release its Q3 2026 resultson Wednesday, November 11th. Analysts expect Korro Bio to post earnings of ($1.2619) per share and revenue of $0.19 million for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.07) EPS for the quarter, topping the consensus estimate of ($1.34) by $0.27. On average, analysts expect Korro Bio to post ($4.95) EPS for the current fiscal year and ($4.46) EPS for the next fiscal year.

Korro Bio Trading Up 0.1%

NASDAQ:KRRO opened at $15.86 on Wednesday. Korro Bio has a one year low of $5.20 and a one year high of $38.42. The stock has a 50-day simple moving average of $11.51 and a 200 day simple moving average of $11.96.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wall Street Zen upgraded Korro Bio from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Korro Bio in a research report on Tuesday, October 6th. Jefferies Financial Group set a $15.00 price target on Korro Bio in a report on Tuesday, October 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Korro Bio in a research report on Friday, October 2nd. Three investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Korro Bio has an average rating of “Moderate Buy” and a consensus price target of $16.50.

Insider Activity

In other Korro Bio news, major shareholder Lynx1 Capital Management Lp purchased 52,175 shares of the firm’s stock in a transaction dated Thursday, October 22nd. The stock was acquired at an average cost of $10.72 per share, with a total value of $559,316.00. Following the acquisition, the insider owned 1,597,155 shares of the company’s stock, valued at approximately $17,121,501.60. This represents a 3.38% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Oliver Dolan sold 7,347 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $13.51, for a total transaction of $99,257.97. Following the sale, the senior vice president directly owned 16,252 shares of the company’s stock, valued at approximately $219,564.52. This represents a 31.13% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders acquired 86,493 shares of company stock valued at $963,734 and sold 38,269 shares valued at $532,064. Company insiders own 4.80% of the company’s stock.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company’s approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient’s DNA.

Korro Bio’s technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease.